Media and Public Relations

Where Innovation Is Tradition

Media Sources Guide

TOPIC: ProteomicsClear

Photo of Expert

Lance A. Liotta

University Professor and Co-director, Center for Applied Proteomics and Molecular Medicine

Web Site

Expertise: Health Care, Cancer, Nanotechnology, Bioengineering, Proteomics, Biomarkers

One of the first scientists to investigate the process of tumor invasion and metastasis at the molecular level, Liotta has invented technologies in the fields of diagnostics, immunoassays, microdissection, and proteomics that have been used to make broad discoveries in genomics, functional genetics, and tissue proteomics. Prior to joining George Mason University, he served as chief of the Laboratory of Pathology at the National Cancer Institute Center for Cancer Research and as deputy director for Intramural Research at the National Institutes of Health. Liotta earned a medical degree and a doctoral degree in biomedical engineering from Case Western Reserve University. His research contributions have generated 90 issued patents and more than 600 articles in peer-reviewed publications. Included among Liotta’s numerous awards for cancer research are three Public Health Service Commissioned Corps medals, the Arthur S. Fleming Award, the Warner Lambert/Parke Davis Award, the Rhoads Memorial Award, the Milken Family Foundation Award for Basic Research, the Lila Gruber Cancer Research Award, the U.S. Surgeon General’s Medallion, and the Maud L. Menten Lecture Award. In addition, he is the recipient of the National Institutes of Health Award of Merit, the Cotlove Research Award, the Ballantyne Distinguished Lectureship Research Award, and the Philip Levine Award for Outstanding Research.

Liotta and Center for Applied Proteomics and Molecular Medicine Co-director Emanuel F. Petricoin III, who are internationally recognized for their pioneering research in proteomics and molecular medicine, co-founded the George Mason University Center for Applied Proteomics and Molecular Medicine in 2005. They currently are exploring their recent discovery of an archive of protein fragments in the blood that are biomarker candidates for breast, ovarian, and lung cancers. Their immediate goals are to validate these potential biomarkers in clinical trials to determine their feasibility in the diagnosis of cancer prior to metastasis, and to analyze molecular pathways in diseased tissue to determine individualized and targeted treatments for patients. The team also is investigating the development and use of nanotechnology to synergize with proteomic tools for new types of biosensors, nanoparticles for biomarker discovery, and nanoelectronics. Liotta and Petricoin have more than 20 patents pending in the areas of cancer theranostics, biomarkers, and related technologies.

Media Contact: Michele McDonald, 703-993-8781, mmcdon15@gmu.edu

Photo of Expert

Aarthi Narayanan

Research Assistant Professor

Web Site

Expertise: Proteomics, vaccines, viral, infecticious diseases, HIV,

Aarthi Narayanan completed her PhD at the University of Georgia; her post doctoral research at the Fred Hutchinson Cancer Research Center in Seattle and the National Institutes of Health in Maryland.

"The first major focus of my research is to understand host responses to infection by bunyaviruses such as Rift Valley fever virus (RVFV), alphaviruses such as Venezuelan Equine Encephalitis Virus (VEEV) and human retroviruses such as HIV.  Specifically, I am interested in deciphering the influences of specific phosphosignaling events occurring in infected host cells that correlate with viral replication and in utilizing such events that are crucial for pathogen replication to design novel therapeutic inhibitors.  In addition to identifying novel therapeutic candidates, my research interest also extends to defining the mechanistic basis behind pathogen inhibition when using host-based therapeutics."

"The second aspect of my research focus includes extracellular membranous vesicles called exosomes, specifically those produced by virally infected cells (Bunyaviruses, Alphaviruses, Human retroviruses).  Exosomes from infected cells will differ significantly in a proteomic and genomic capacity from those produced by uninfected cells.  Such information can be exploited to understand transfer for genetic and proteomic information to naïve cells (intercellular communication).   Such information can also be utilized to discover novel disease/pathogen specific biomarkers, vaccine and therapeutic candidates."

 

Media Contact: Michele McDonald, 703-993-8781, mmcdon15@gmu.edu

Photo of Expert

Emanuel "Chip" Petricoin III

University Professor and Co-director, Center for Applied Proteomics and Molecular Medicine

Web Site

Expertise: Health Care, Cancer, Nanotechnology, Proteomics, Biomarkers

A renowned proteomics and cell signaling expert, Petricoin came to George Mason University from the U.S. Food and Drug Administration Center for Biologics Evaluation and Research, where he served as a senior investigator. His expertise also includes drug and biologic effects on signal transduction and kinase-driven cascades, diagnostic platform development, pathogenic microbiology, and artificial intelligence-based bioinformatics tools.

Petricoin holds a doctorate in microbiology from the University of Maryland at College Park. He serves on numerous editorial boards, has co-written more than 170 articles for peer-reviewed publications, and is a member of the American Association for Cancer Research.

Petricoin and Center for Applied Proteomics and Molecular Medicine Co-director Lance A. Liotta, who are internationally recognized for their pioneering research in proteomics and molecular medicine, co-founded the George Mason University Center for Applied Proteomics and Molecular Medicine in 2005. They currently are exploring their recent discovery of an archive of protein fragments in the blood that are biomarker candidates for breast, ovarian, and lung cancers. Their immediate goals are to validate these potential biomarkers in clinical trials to determine their feasibility in the diagnosis of cancer prior to metastasis, and to analyze molecular pathways in diseased tissue to determine individualized and targeted treatments for patients. The team also is investigating the development and use of nanotechnology to synergize with proteomic tools for new types of biosensors, nanoparticles for biomarker discovery, and nanoelectronics. Liotta and Petricoin have more than 20 patents pending in the areas of cancer theranostics, biomarkers, and related technologies.

Media Contact: Michele McDonald, 703-993-8781, mmcdon15@gmu.edu